JCLA:VDR-FokI和VDBP-Thr420Lys多态性与脊髓型颈椎病的关系:中国人群的病例对照研究

2019-06-06 不详 网络

脊髓型颈椎病(CSM)是一种常见的退行性疾病,该疾病的特点是慢性进行性压迫颈椎脊髓。本病例对照研究旨在探讨VDR‐FokI和VDBP‐Thr420Lys多态性在中国人群CSM易感性中的潜在作用。 本研究纳入318例CSM患者和282例健康个体,并对其临床资料进行回顾性分析。采用聚合酶链反应限制片段长度多态性(PCR‐RFLP)分析方法对VDR‐FokI和VDBP‐Thr420Lys多态性进行

脊髓型颈椎病(CSM)是一种常见的退行性疾病,该疾病的特点是慢性进行性压迫颈椎脊髓。本病例对照研究旨在探讨VDRFokIVDBPThr420Lys多态性在中国人群CSM易感性中的潜在作用。

本研究纳入318CSM患者和282例健康个体,并对其临床资料进行回顾性分析。采用聚合酶链反应限制片段长度多态性(PCRRFLP)分析方法对VDRFokIVDBPThr420Lys多态性进行基因型分析。采用日本骨科协会(JOA)评分和颈椎磁共振成像(MRI)评定CSM的严重程度。采用非条件二项logistic回归模型对CSM的危险因素进行了评价。

研究发现,CSM组患者弯腰伏案工作的时间较对照组长。CSM患者中,VDRFokIff基因型和f等位基因频率升高。VDRFokIFf + Ff基因型和f等位基因频率升高可能增加CSM的风险。VDRFokI多态性与髓核毛细血管浸润、坏死、玻璃样变性和纤维化、软骨样细胞的发生和增生以及纤维环中的纤维囊肿有关。VDRFokIVDBPThr420Lys基因型符合HardyWeinberg平衡,表明VDRFokIVDBPThr420Lys具有群体表征特征。

二元logistic回归分析证实VDRFokI多态性和伏案工作时间是CSM的危险因素。因此,结果表明,VDRFokI多态性可能与CSM的风险密切相关。

原始出处:

DeWei Song, YuDong Wu, Association of VDRFokI and VDBPThr420Lys polymorphisms with cervical spondylotic myelopathy: A casecontrol study in the population of China

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2058213, encodeId=54e320582139a, content=<a href='/topic/show?id=a7f3183222b' target=_blank style='color:#2F92EE;'>#VDR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18322, encryptionId=a7f3183222b, topicName=VDR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Feb 03 15:32:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984136, encodeId=b5701984136ba, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Jan 30 01:32:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756166, encodeId=30be1e56166c5, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Sun Oct 06 00:32:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775462, encodeId=75501e7546244, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Dec 12 10:32:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575688, encodeId=eded15e56886b, content=<a href='/topic/show?id=f5598459992' target=_blank style='color:#2F92EE;'>#脊髓型颈椎病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84599, encryptionId=f5598459992, topicName=脊髓型颈椎病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e89e16147789, createdName=w984450tii, createdTime=Sat Jun 08 13:32:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629281, encodeId=d3d61629281b3, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Sat Jun 08 13:32:00 CST 2019, time=2019-06-08, status=1, ipAttribution=)]
    2020-02-03 zhyy88
  2. [GetPortalCommentsPageByObjectIdResponse(id=2058213, encodeId=54e320582139a, content=<a href='/topic/show?id=a7f3183222b' target=_blank style='color:#2F92EE;'>#VDR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18322, encryptionId=a7f3183222b, topicName=VDR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Feb 03 15:32:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984136, encodeId=b5701984136ba, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Jan 30 01:32:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756166, encodeId=30be1e56166c5, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Sun Oct 06 00:32:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775462, encodeId=75501e7546244, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Dec 12 10:32:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575688, encodeId=eded15e56886b, content=<a href='/topic/show?id=f5598459992' target=_blank style='color:#2F92EE;'>#脊髓型颈椎病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84599, encryptionId=f5598459992, topicName=脊髓型颈椎病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e89e16147789, createdName=w984450tii, createdTime=Sat Jun 08 13:32:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629281, encodeId=d3d61629281b3, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Sat Jun 08 13:32:00 CST 2019, time=2019-06-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2058213, encodeId=54e320582139a, content=<a href='/topic/show?id=a7f3183222b' target=_blank style='color:#2F92EE;'>#VDR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18322, encryptionId=a7f3183222b, topicName=VDR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Feb 03 15:32:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984136, encodeId=b5701984136ba, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Jan 30 01:32:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756166, encodeId=30be1e56166c5, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Sun Oct 06 00:32:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775462, encodeId=75501e7546244, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Dec 12 10:32:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575688, encodeId=eded15e56886b, content=<a href='/topic/show?id=f5598459992' target=_blank style='color:#2F92EE;'>#脊髓型颈椎病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84599, encryptionId=f5598459992, topicName=脊髓型颈椎病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e89e16147789, createdName=w984450tii, createdTime=Sat Jun 08 13:32:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629281, encodeId=d3d61629281b3, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Sat Jun 08 13:32:00 CST 2019, time=2019-06-08, status=1, ipAttribution=)]
    2019-10-06 xugc
  4. [GetPortalCommentsPageByObjectIdResponse(id=2058213, encodeId=54e320582139a, content=<a href='/topic/show?id=a7f3183222b' target=_blank style='color:#2F92EE;'>#VDR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18322, encryptionId=a7f3183222b, topicName=VDR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Feb 03 15:32:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984136, encodeId=b5701984136ba, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Jan 30 01:32:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756166, encodeId=30be1e56166c5, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Sun Oct 06 00:32:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775462, encodeId=75501e7546244, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Dec 12 10:32:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575688, encodeId=eded15e56886b, content=<a href='/topic/show?id=f5598459992' target=_blank style='color:#2F92EE;'>#脊髓型颈椎病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84599, encryptionId=f5598459992, topicName=脊髓型颈椎病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e89e16147789, createdName=w984450tii, createdTime=Sat Jun 08 13:32:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629281, encodeId=d3d61629281b3, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Sat Jun 08 13:32:00 CST 2019, time=2019-06-08, status=1, ipAttribution=)]
    2019-12-12 amyloid
  5. [GetPortalCommentsPageByObjectIdResponse(id=2058213, encodeId=54e320582139a, content=<a href='/topic/show?id=a7f3183222b' target=_blank style='color:#2F92EE;'>#VDR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18322, encryptionId=a7f3183222b, topicName=VDR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Feb 03 15:32:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984136, encodeId=b5701984136ba, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Jan 30 01:32:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756166, encodeId=30be1e56166c5, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Sun Oct 06 00:32:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775462, encodeId=75501e7546244, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Dec 12 10:32:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575688, encodeId=eded15e56886b, content=<a href='/topic/show?id=f5598459992' target=_blank style='color:#2F92EE;'>#脊髓型颈椎病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84599, encryptionId=f5598459992, topicName=脊髓型颈椎病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e89e16147789, createdName=w984450tii, createdTime=Sat Jun 08 13:32:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629281, encodeId=d3d61629281b3, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Sat Jun 08 13:32:00 CST 2019, time=2019-06-08, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2058213, encodeId=54e320582139a, content=<a href='/topic/show?id=a7f3183222b' target=_blank style='color:#2F92EE;'>#VDR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18322, encryptionId=a7f3183222b, topicName=VDR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Feb 03 15:32:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984136, encodeId=b5701984136ba, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Jan 30 01:32:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756166, encodeId=30be1e56166c5, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Sun Oct 06 00:32:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775462, encodeId=75501e7546244, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Dec 12 10:32:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575688, encodeId=eded15e56886b, content=<a href='/topic/show?id=f5598459992' target=_blank style='color:#2F92EE;'>#脊髓型颈椎病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84599, encryptionId=f5598459992, topicName=脊髓型颈椎病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e89e16147789, createdName=w984450tii, createdTime=Sat Jun 08 13:32:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629281, encodeId=d3d61629281b3, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Sat Jun 08 13:32:00 CST 2019, time=2019-06-08, status=1, ipAttribution=)]
    2019-06-08 xzw120

相关资讯

Exp Biol Med:IL1A和IL1B多态性与巴西人群中原发性开角型青光眼的关系

巴西坎皮纳斯大学CBMEG分子生物学和基因工程中心人类遗传学实验室的Oliveira MB等人近日在Exp Biol Med杂志上发表了一篇重要的工作,他们首次揭示了青光眼与功能性-31C / T单核苷酸多态性之间的关联性。

J Viral Hepat:Toll样受体4多态性与印度患者感染戊型肝炎病毒的关系

研究首次报道了TLR4多态性与戊型肝炎的关系,并提示HEV感染时TLR4低反应性可能与其多态性有关。

Sci Rep:类风湿性关节炎患者甲氨蝶呤治疗反应相关多态性的验证研究

根据ΔDAS28(P = 0.0016)和EULAR反应(P = 0.004),其小的等位基因的改善程度低于大的等位基因,这与性别、年龄、基线DAS28、吸烟、血清学阳性、同时使用糖皮质激素或既往治疗无关。

PLos One:雷诺现象与NOS1基因多态性的关联

结果表明RP与基因NOS1的变异相关。这一发现可能与已知的NOS1中的SNP对基因表达有功能影响有关。

CCLM:基于ADRB1 Ser49Gly和Arg389Gly多态性的原发性高血压患者外周血单个核细胞mRNA表达谱?

β1肾上腺素受体(ADRB1)的遗传多态性被广泛地应用于许多心血管疾病易感性研究,如高血压病。然而,对ADRB1的mRNA表达的研究却很少。 本研究是一项包含292例高血压患者和324例对照的病例对照试验。研究旨在评估Ser49Gly和Arg389Gly的作用,这些研究通常是对与原发性高血压的遗传倾向有关的ADRB1的mRNA水平上单核苷酸多态性(SNP)的研究。 结果显示,基于Ser

J Viral Hepat:IFNAR2 -rs1051393, rs12233338可能是中国人群HBV感染的预测标志物

IFNAR2 -rs1051393, rs12233338可能是中国人群HBV感染的预测标志物